Tags

Type your tag names separated by a space and hit enter

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Mov Disord. 2004 May; 19(5):554-60.MD

Abstract

Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia.

Authors+Show Affiliations

The Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom. sfox@uhnres.utoronto.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15133820

Citation

Fox, Susan, et al. "Non-subtype-selective Opioid Receptor Antagonism in Treatment of Levodopa-induced Motor Complications in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 19, no. 5, 2004, pp. 554-60.
Fox S, Silverdale M, Kellett M, et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord. 2004;19(5):554-60.
Fox, S., Silverdale, M., Kellett, M., Davies, R., Steiger, M., Fletcher, N., Crossman, A., & Brotchie, J. (2004). Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 19(5), 554-60.
Fox S, et al. Non-subtype-selective Opioid Receptor Antagonism in Treatment of Levodopa-induced Motor Complications in Parkinson's Disease. Mov Disord. 2004;19(5):554-60. PubMed PMID: 15133820.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. AU - Fox,Susan, AU - Silverdale,Montague, AU - Kellett,Mark, AU - Davies,Rhys, AU - Steiger,Malcolm, AU - Fletcher,Nicholas, AU - Crossman,Alan, AU - Brotchie,Jonathan, PY - 2004/5/11/pubmed PY - 2004/9/24/medline PY - 2004/5/11/entrez SP - 554 EP - 60 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 19 IS - 5 N2 - Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15133820/Non_subtype_selective_opioid_receptor_antagonism_in_treatment_of_levodopa_induced_motor_complications_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.10693 DB - PRIME DP - Unbound Medicine ER -